Carol A. Vallone - Jun 1, 2022 Form 4/A - Amendment Insider Report for Mind Medicine (MindMed) Inc. (MNMD)

Role
Director
Signature
/s/ Robert Barrow, Attorney-in-Fact
Stock symbol
MNMD
Transactions as of
Jun 1, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
6/6/2022, 04:11 PM
Date Of Original Report
Jun 3, 2022
Previous filing
Jan 10, 2022
Next filing
Jun 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNMD Subordinate Voting Shares Award $0 +43.1K $0.00 43.1K Jun 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNMD Stock Option (Right to Buy) Award $0 +134K +480.35% $0.00 162K Jun 1, 2022 Subordinate Voting Shares 134K $0.60 Direct F2, F3
transaction MNMD Director's Deferred Share Units Award +98.2K +352.68% 126K Jun 1, 2022 Subordinate Voting Shares Direct F4
transaction MNMD Director's Deferred Share Units Award +775K +2782.29% 803K Jun 1, 2022 Subordinate Voting Shares Direct F5
transaction MNMD Director's Deferred Share Units Award +34.4K +123.38% 62.2K Jun 1, 2022 Subordinate Voting Shares Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. Of these RSUs, 8/12ths of the RSUs vested and became exercisable on June 1, 2022, with the remaining 4/12ths of the total RSUs vesting on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such vesting date.
F2 The option grant has an exercise price of $0.75 Canadian Dollars. This represents the exercise price in United States Dollars.
F3 8/12ths of the shares underlying the options vested and became exercisable on June 1, 2022; the remaining shares underlying the option shall vest and become exercisable with 1/12th of the total shares vesting on each of June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date.
F4 Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan).
F5 Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan).
F6 Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan).

Remarks:

Explanatory Note: This Amendment on Form 4/A is being filed to amend the Form 4 filed on June 3, 2022 solely to update the Expiration Date of the Stock Option in Table 2.